A California medical device company developing an automated glucose monitoring system for critically ill patients in the intensive care unit raised $5 million, according to two regulatory filings in October.
OptiScan Biomedical, based in Hayward, is developing the OptiScanner, which the company is billing as the first-of-its bedside continuous glucose monitoring systems able to provide readings every 15 minutes. The company’s website notes that because of frequent readings, the OptiScanner can provide glycemic trends that can tell providers whether the glucose levels are stable, rising too high or falling too low. If the levels are outside the target range, the display shows that in the color red and alerts the provider. When they fall within the normal range, the levels are shown in green.
An email to Patrick Nugent, OptiScan’s chief financial officer, wasn’t immediately returned.
The OptiScanner obtained the CE Mark in September 2011 and a news release from March shows that the company was preparing for a commercial launch in Europe. The product is not available in the U.S.
